Reviewed by Laurence P. Banville, Esq.Frequently asked questions
What is canagliflozin and why are there lawsuits?
Canagliflozin is the active ingredient in Invokana, a type 2 diabetes drug made by Janssen Pharmaceuticals. Lawsuits allege it causes serious side effects including lower limb amputations, diabetic ketoacidosis (DKA), acute kidney injury, and bone fractures. Plaintiffs argue the manufacturer failed to adequately warn patients and prescribing physicians about these risks.
What injuries qualify for a canagliflozin lawsuit in New York?
In New York, you may be eligible to file a product liability claim if you took canagliflozin and suffered a lower limb amputation, diabetic ketoacidosis, acute kidney injury or kidney failure, or serious bone fractures. The FDA issued a Black Box Warning in 2017 for amputation risk and updated its DKA warnings in 2015, strengthening the basis for failure-to-warn claims under NY law.
How long do I have to file a canagliflozin lawsuit in New York?
New York’s statute of limitations for personal injury and product liability claims is three years under CPLR §214. The clock generally starts when you were injured or when you reasonably discovered the injury was linked to canagliflozin. Because calculating this deadline can be complex, New York courts apply a discovery rule in some pharmaceutical cases — consult an attorney as soon as possible to protect your rights.
What compensation can I seek in a New York canagliflozin lawsuit?
Eligible New York plaintiffs may seek compensation for medical expenses (including amputation surgery and rehabilitation), lost wages, pain and suffering, and long-term disability costs. New York does not cap compensatory damages in personal injury cases, though each case depends on individual facts and injuries. No specific outcome is guaranteed, and you should speak with an attorney to evaluate your claim.